Clinical Trial Update: A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC [Phase 2]

View source ↗

Summary

This Phase II trial investigates Benmelstobart in combination with Anlotinib and chemotherapy as first-line therapy for large-cell neuroendocrine carcinoma of t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma
• Large Cell Neuroendocrine Carcinoma of the Lung

Drugs mentioned

• Anlotinib (anlotinib)
• Benmelstobart

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING